Letters sent to healthcare professionals in February 2018

Letters were sent about ellaOne, ERWINASE, Eperzan鈻�, Ocaliva鈻�, Velcade, Esmya, and Bleo-Kyowa.

From:
Medicines and Healthcare products Regulatory Agency
Published
8 March 2018
Therapeutic area:
Anaesthesia and intensive care, Cancer, Cardiovascular disease and lipidology, Endocrinology, diabetology and metabolism and GI, hepatology and pancreatic disorders
Show 7 more
Haematology and oncology, Immunosuppression and transplantation, Infectious disease, Neurology, Obstetrics, gynaecology and fertility, Paediatrics and neonatology, and Urology and nephrology

In February 2018, letters were sent to healthcare professionals about:

  • ellaOne post-marketing surveillance:
  • Ocaliva鈻� (obeticholic acid):
  • ERWINASE:
  • Bleo-Kyowa (bleomycin sulphate), powder for solution for injection 鈥� 鈥� see Class 4 Medicine Defect Information alert
  • Velcade (bortezomib) 3.5 mg vials:
  • Restrictions on the use of ulipristal acetate, Esmya 5 mg tablet,
  • 贰辫别谤锄补苍鈻�(补濒产颈驳濒耻迟颈诲别):

Article citation: Drug Safety Update volume 11 issue 8; March 2018: 5.

Updates to this page

Published 8 March 2018

Related content